David M Gershenson

10PUBLICATIONS
90CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Dec 09, 2024
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors.

Thomas Welte, Veena K Vuttaradhi, Eleonora Y Khlebus

|Oct 12, 2024
TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors.

Allison L Brodsky, Alejandra Flores Legarreta, Bryan M Fellman

|Oct 07, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen

|Apr 30, 2024
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.

Ji Son, Yingao Zhang, Heather Lin

Pageof 2

Frequent Collaborators

4 joint publications

Robert Tyler Hillman

4 joint publications

Anil K Sood

3 joint publications

Barrett Lawson

3 joint publications

Susana Banerjee